-+ 0.00%
-+ 0.00%
-+ 0.00%

Promontory Therapeutics Announces Interim Efficacy Requirement Reached on Phase 2 Study of PT-112 Monotherapy in Patients with Recurrent Thymoma

Barchart·12/22/2025 08:00:00
Listen to the news

Three of the first 10 patients with thymoma evaluated by RECIST have partial responses.

Findings exceed protocol requirement of two responses among first 16 patients evaluated to proceed with stage 2 of efficacy assessment.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.